Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03282591 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
A Phase 2 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
NCT03282591 is a Phase 2 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 185 participants.
The verdict
NCT03282591, a Phase 2 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
Study Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
Interventions
- DRUG 5 mg Serlopitant Tablets
- DRUG Matching Placebo Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2018-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03282591
The ClinicalTrials.gov registry entry for NCT03282591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5 mg Serlopitant Tablets is the first listed.
NCT03282591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03282591 about?
NCT03282591 is a clinical study titled "Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough". Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
What is the current status of trial NCT03282591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2017-10-03. Estimated completion is 2018-09-06.
What interventions are being tested in trial NCT03282591?
The interventions under investigation include: 5 mg Serlopitant Tablets (DRUG), Matching Placebo Tablets (DRUG).
Who is sponsoring clinical trial NCT03282591?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.